Villejuif, near Paris, France, November 30, 2021 – EverImmune, a biotechnology company specialized in the development of live biotherapeutic products in the field of microbiota oncology, today announces it has raised more than €5 million (approx. $6M) in a Series A funding from undisclosed private investors. EverImm.